ALNEO included patients with potentially resectable disease and treated them with neoadjuvant alectinib for two cycles, ...

Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In t ...

Experienced oncology nurses and APPs can help nurses newer to the field understand who is more at risk of opioid addiction, ...